CN Patent

CN1543462A — 包括n－[2－(二乙氨基)乙基]－5－[(5－氟－2－氧代－3h－吲哚－3－亚基)甲基]－2,4－二甲基－1h－吡咯－3－甲酰胺的苹果酸盐的晶体、其制备方法和其组合物

Assigned to Pharmacia and Upjohn Co LLC · Expires 2004-11-03 · 22y expired

What this patent protects

本发明提供晶体及其组合物，其中该晶体包括N－[2－(二乙氨基)乙基]－5－[(5－氟－1，2－二氢－2－氧代－3H－吲哚－3－亚基)甲基]－2，4－二甲基－1H－吡咯－3－甲酰胺的苹果酸盐。还公开了制备这类晶体的方法。

USPTO Abstract

本发明提供晶体及其组合物，其中该晶体包括N－[2－(二乙氨基)乙基]－5－[(5－氟－1，2－二氢－2－氧代－3H－吲哚－3－亚基)甲基]－2，4－二甲基－1H－吡咯－3－甲酰胺的苹果酸盐。还公开了制备这类晶体的方法。

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN1543462A
Jurisdiction: CN
Classification: —
Expires: 2004-11-03
Drug substance claim: No
Drug product claim: No
Assignee: Pharmacia and Upjohn Co LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.